Results 31 to 40 of about 14,984 (246)
Reaction of N,N-Dimethyltryptamine with Dichloromethane Under Common Experimental Conditions. [PDF]
, 2018 A large number of clinically used drugs and experimental pharmaceuticals possess the N,N-dimethyltryptamine (DMT) structural core. Previous reports have described the reaction of this motif with dichloromethane (DCM), a common laboratory solvent used ...
Dunlap, Lee E, Olson, David E
core +3 more sources
Psychedelic Cognition—The Unreached Frontier of Psychedelic Science
Frontiers in Neuroscience, 2022 Psychedelic compounds hold the promise of changing the face of neuroscience and psychiatry as we know it. There have been numerous proposals to use them to treat a range of neuropsychiatric conditions such as depression, anxiety, addiction and PTSD; and trials to date have delivered positive results in favor of the novel therapeutics.
openaire +5 more sources
Psychedelics and Personality [PDF]
ACS Chemical Neuroscience, 2018 In the past decade, an increasing number of clinical trials are reporting evidence that psychedelics or serotonergic hallucinogens (such as lysergic acid diethylamide, psilocybin, and ayahuasca/dimethyltryptamine) could be effective in the treatment of mood, anxiety, and substance use disorders.
Marc, Aixalà +3 more
openaire +2 more sources
Frontiers in Psychiatry, 2021 Introduction: The current corona virus disease (COVID-19) pandemic has caused a serious global health crisis that has affected large parts of the public and private life worldwide, including the use of psychoactive substances.
Ricarda Evens +19 more
doaj +1 more source
Frontiers in Psychiatry, 2023 IntroductionThere is substantial public interest in psychedelics as potential treatments for psychiatric conditions. However, most psychedelics are criminalized under federal law in the USA, so it is unclear whether use occurs with clinical support.
Kevin F. Boehnke +17 more
doaj +1 more source
Investigating Emotional Reactivity in Experienced Users of Psychedelics: A Cross-Sectional fMRI Study. [PDF]
Hum Brain MappThis cross‐sectional fMRI study compared experienced psychedelic users and matched nonusers on behavioral and neural responses to emotional facial expressions. Findings reveal neurofunctional differences between groups in emotional reactivity, highlighting both similarities and important distinctions in the long‐term effects of naturalistic versus ...
Orłowski P, Domagalik A, Bola M.
europepmc +2 more sources
Frontiers in PsychiatryIntense interest surrounds current research on psychedelics, particularly regarding their potential in treating mental health disorders. Various studies suggest a link between the subjective effects produced by psychedelics and their therapeutic efficacy.
Zijia Yu +20 more
doaj +1 more source
Psychedelics: A new era of treatment?
European Psychiatry, 2021 Introduction Psychedelics - including LSD (lysergic acid diethylamide), psilocybin, DMT (N, N-dimethyltryptamine), ayahuasca and mescaline - have an ancient history across various civilizations.
S. Torres
doaj +1 more source
Nature CommunicationsPsilocybin increases social connectedness and has strong clinical transdiagnostic efficacy for mental illness, making it a candidate treatment to reduce maternal disconnect, anxiety, and blunted affect seen in peripartum mood disorders.
Cassandra J. Hatzipantelis +15 more
doaj +1 more source
Cannabis-based extract for managing pain in dogs with osteoarthritis: efficacy and safety assessment
Frontiers in PharmacologyIntroductionCanine osteoarthritis (OA) is a prevalent disease characterized by progressive joint degeneration, pain, and impaired mobility. In older dogs, OA affects approximately 80% of the population.
Neide Maria Griebeler +12 more
doaj +1 more source